These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 33710337)
41. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant. Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755 [TBL] [Abstract][Full Text] [Related]
42. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695 [TBL] [Abstract][Full Text] [Related]
43. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476 [TBL] [Abstract][Full Text] [Related]
44. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience. Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224 [TBL] [Abstract][Full Text] [Related]
45. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953 [TBL] [Abstract][Full Text] [Related]
46. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590 [TBL] [Abstract][Full Text] [Related]
47. Outcomes of Autologous Stem Cell Transplantation (ASCT) in Relapsed/Refractory Germ Cell Tumors: Single Center Experience from Turkey. Yildiz F; Durnali A; Eraslan E; Ilhan A; Tufan G; Aslan F; Arslan UY; Alkis N; Demirci U; Altuntas F; Oksuzoglu B Urol J; 2020 Aug; 17(5):497-500. PubMed ID: 32869258 [TBL] [Abstract][Full Text] [Related]
48. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904 [TBL] [Abstract][Full Text] [Related]
49. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients. Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627 [TBL] [Abstract][Full Text] [Related]
51. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660 [TBL] [Abstract][Full Text] [Related]
52. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649 [TBL] [Abstract][Full Text] [Related]
53. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells. Guolo F; Minetto P; Pesce S; Ballerini F; Clavio M; Cea M; Frello M; Garibotto M; Greppi M; Bozzo M; Miglino M; Passannante M; Marcolin R; Tedone E; Colombo N; Mangerini R; Bo A; Ruzzenenti MR; Carlier P; Serio A; Luchetti S; Dominietto A; Varaldo R; Candiani S; Agostini V; Ravetti JL; Del Zotto G; Marcenaro E; Lemoli RM Front Immunol; 2021; 12():753890. PubMed ID: 34804039 [TBL] [Abstract][Full Text] [Related]
54. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. Merrill MH; Dahi PB; Redd RA; McDonough MM; Chen YB; DeFilipp Z; Herrera AF; Fisher DC; LaCasce AS; Odejide OO; Ng SY; Jacobson CA; Merryman RW; Kim AI; Nieto YL; Sauter CS; Shah GL; Zain JM; Armand P; Jacobsen ED Blood; 2023 Aug; 142(7):621-628. PubMed ID: 37319432 [TBL] [Abstract][Full Text] [Related]
56. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant. Qiao W; Zhao J; Xing Y; Wang C; Wang T Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323 [TBL] [Abstract][Full Text] [Related]
58. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. Keller SF; Kelly JL; Sensenig E; Andreozzi J; Oliva J; Rich L; Constine L; Becker M; Phillips G; Liesveld J; Fisher RI; Bernstein SH; Friedberg JW Biol Blood Marrow Transplant; 2012 Apr; 18(4):640-7. PubMed ID: 21871246 [TBL] [Abstract][Full Text] [Related]
59. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Qiao W; Zhao J; Wang C; Wang T; Xing Y Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658 [TBL] [Abstract][Full Text] [Related]
60. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]